A currently recruiting Phase 2 clinical trial from Sanofi, “Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (ESTAIR),” will be investigating how a novel antibody treatment may help patients with idiopathic pulmonary fibrosis (IPF). The novel therapeutic,…
News
The American Thoracic Society (ATS) now recommends that some patients with idiopathic pulmonary fibrosis (IPF) are eligible to be treated with Genentech’s Esbriet ® (pirfenidone). The conditional recommendation was based on three Phase 3 clinical trials of Esbriet vs. placebo in patients with IPF. In…
Australia-based pharmaceutical company Pharmaxis Ltd. recently agreed to collaborate with UK-based biotechnology company Synairgen plc in developing a selective inhibitor of lysyl oxidase type 2 enzyme (LOXL2) to treat idiopathic pulmonary fibrosis (IPF), as this enzyme drives scar tissue formation. If LOXL2 is inhibited, survival rates of patients with IPF may…
Pharmaxis Ltd. and Synairgen plc are entering into a research collaboration to develop a therapeutic for idiopathic pulmonary fibrosis (IPF). The two companies are researching a selective inhibitor of the lysyl oxidase type 2 enzyme (LOXL2), an enzyme shown to promote scar tissue and damage in the lungs of IPF…
An accumulation of data from multiple different studies supports the use of pirfenidone (Esbriet, from Roche) to treat idiopathic pulmonary fibrosis. One study in Belgium and the Netherlands demonstrated strong safety and efficacy profiles, and two more studies in the United States suggested a reduction in disease progression following treatment.
Moerae Matrix Inc. recently announced the start of a second Phase 1 clinical trial with MMI-0100, a therapeutic drug developed for pulmonary disorders associated with fibrosis and inflammation, as is the case with idiopathic pulmonary fibrosis (IPF). IPF is a progressive fatal lung disease in which the alveoli and the…
A new study led by researchers at the Comprehensive Pneumology Center (CPC) at Helmholtz Zentrum Munich in Germany recently revealed a new mechanism that contributes to the development of idiopathic pulmonary fibrosis (IPF). The study is entitled “Regulation of 26S Proteasome Activity in Pulmonary Fibrosis” and…
A new study recently published in the journal Respirology reviewed the growing evidence of a link between cigarette smoking and the development of interstitial lung diseases (ILD) including idiopathic pulmonary fibrosis (IPF). The study is entitled “Smoking-related idiopathic interstitial pneumonia: A review” and was developed…
Pulmatrix, Inc. a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology, has been granted two patents from the U.S. Patent and Trademark Office, covering the composition of matter for iSPERSE™ as well as methods for treating patients using respirable dry…
MediciNova, Inc., a publicly-traded biopharmaceutical company working on developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that it is in late-stage discussions with researchers at Penn State University (lead researcher Dr. Rebecca Bascom) to begin a Phase 2 clinical trial of MN-001 (tipelukast) for…
